Immunogenicity and safety of a novel monovalent high-dose inactivated poliovirus type 2 vaccine in infants: a comparative, observer-blind, randomised, controlled trial

Summary Background Following the proposed worldwide switch from trivalent oral poliovirus vaccine (tOPV) to bivalent types 1 and 3 OPV (bOPV) in 2016, inactivated poliovirus vaccine (IPV) will be the only source of protection against poliovirus type 2. With most countries opting for one dose of IPV...

Full description

Saved in:

Bibliographic Details
Published in:	The Lancet infectious diseases Vol. 16; no. 3; pp. 321 - 330
Main Authors:	Sáez-Llorens, Xavier, MD, Clemens, Ralf, MD, Leroux-Roels, Geert, MD, Jimeno, José, MD, Clemens, Sue Ann Costa, MD, Weldon, William C, PhD, Oberste, M Steven, PhD, Molina, Natanael, PharmD, Bandyopadhyay, Ananda S, Dr
Format:	Journal Article
Language:	English
Published:	United States Elsevier Ltd 01-03-2016 Elsevier Limited
Subjects:	Age Antibodies, Viral - blood Enterovirus Feces - virology Female Hepatitis Humans Immunization Immunogenicity Infant Infants Infectious Disease Infectious diseases Male Picornaviridae Poliomyelitis Poliomyelitis - prevention & control Poliovirus Poliovirus - immunology Poliovirus Vaccine, Inactivated - adverse effects Poliovirus Vaccine, Inactivated - immunology Safety Single-Blind Method Studies Vaccination - methods Vaccines Virus Shedding Viruses
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!